New York, USA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Soft Tissue Sarcoma Market to Propel by 2032, Predicts DelveInsight | Key Companies in the Market - Monopar, Jazz, Tracon, C4, Eli Lilly, Epizyme, Ipsen, GlaxoSmithKline, Salarius, Merck, Agenus, Mirati
The emergence of new products in the pipeline will add to the soft tissue sarcoma market growth in the future. In addition, persistently rising cases of soft tissue sarcoma in the forecast period will help increase the soft tissue sarcoma treatment market.
DelveInsight’s Soft Tissue Sarcoma Market Insights report includes a comprehensive understanding of current treatment practices, soft tissue sarcoma emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Soft Tissue Sarcoma Market Report
- As per DelveInsight’s analysis, the soft tissue sarcoma market is anticipated to grow at a significant CAGR by 2032.
- According to the revised statistical estimates of the American Cancer Society (2022), there were about 13,190 newly diagnosed cases of soft tissue sarcoma and approximately 5,130 deaths (2,740 males and 2,390 females) due to soft tissue sarcoma in the US.
- Leading soft tissue sarcoma companies such as Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc., and others are developing novel soft tissue sarcoma drugs that can be available in the soft tissue sarcoma market in the coming years.
- Some of the key therapies for soft tissue sarcoma treatment include Camsirubicin, Lurbinectedin, Liposomal Annamycin (L-Annamycin), AL3818, YH001, CFT8634, Olaratumab + Doxorubicin, Tazemetostat + Doxorubicin HCl, Niraparib, Seclidemstat, Tinostamustine (EDO-S101), HFB301001, Tigilanol Tiglate, Pembrolizumab, Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy, L19TNF and DOXORUBICIN, doxorubicin with AGEN1884 and AGEN2034, APX005M, MGCD516, and others.
Discover which therapies are expected to grab the major soft tissue sarcoma market share @ Soft Tissue Sarcoma Market Report
Soft Tissue Sarcoma Overview
Soft tissue sarcoma is a relatively rare type of cancer that originates in the soft tissues of the body, such as muscles, tendons, fat, blood vessels, and nerves. It can affect people of all ages, but it is more commonly diagnosed in adults. The exact causes of soft tissue sarcoma are not always clear, but certain risk factors have been identified, including exposure to radiation, certain genetic conditions, and prior treatment with certain chemotherapy drugs.
Symptoms of soft tissue sarcoma can vary depending on the location and size of the tumor. Common signs may include a noticeable lump or swelling in the affected area, pain or tenderness, limited mobility, and in some cases, a feeling of pressure or fullness. Since these soft tissue sarcoma symptoms can be indicative of various conditions, it is essential to seek medical attention if they persist or worsen.
Diagnosing soft tissue sarcoma typically involves a combination of imaging tests, such as MRI, CT scans, and ultrasounds, to identify the presence and location of the tumor. A biopsy is then performed, during which a small tissue sample is taken and examined under a microscope to determine if the growth is malignant or benign.
Soft Tissue Sarcoma Epidemiology Segmentation
The soft tissue sarcoma epidemiology section provides insights into the historical and current soft tissue sarcoma patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The soft tissue sarcoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Total Soft Tissue Sarcoma Incident Cases
- Soft Tissue Sarcoma Gender-specific Incident Cases
- Soft Tissue Sarcoma Type-specific Incident Cases
- Soft Tissue Sarcoma Age-specific Incident Cases
- Soft Tissue Sarcoma Stage-specific Incident Cases
- Incident Cases of Soft Tissue Sarcoma by Extremities
Download the report to understand which factors are driving soft tissue sarcoma epidemiology trends @ Soft Tissue Sarcoma Epidemiological Insights
Soft Tissue Sarcoma Treatment Market
Soft tissue sarcoma treatment is typically individualized based on the tumor’s type, location, stage, and the patient's overall health. The mainstays of soft tissue sarcoma treatment include surgery, radiation therapy, and chemotherapy, often used in combination or alone, depending on the specific case. Surgery is the primary treatment for localized soft tissue sarcoma and aims to remove the tumor along with a margin of healthy tissue to minimize the risk of recurrence. In some cases, surgical interventions may involve reconstructive procedures to maintain function and appearance.
Radiation therapy uses high-energy rays to target and destroy cancer cells or shrink tumors before surgery or as a stand-alone treatment for inoperable tumors. It can also be used after surgery to reduce the risk of local recurrence. Chemotherapy may be used for certain types of soft tissue sarcomas that are more likely to spread to other parts of the body. Chemotherapy uses drugs to kill or slow the growth of cancer cells, and it is often administered in cycles to allow the body time to recover between treatments.
In recent years, targeted therapies and immunotherapy have shown promise in the treatment of soft tissue sarcomas, especially for those that do not respond well to traditional treatments. These innovative therapies specifically target certain molecules or stimulate the body's immune system to fight cancer cells. Multidisciplinary teams of oncologists, surgeons, radiation oncologists, and other specialists collaborate to design the most effective soft tissue sarcoma treatment plan for each individual patient. Regular follow-ups and monitoring are crucial to detect any recurrence or potential side effects of treatment. While treating soft tissue sarcoma can present challenges, advancements in medical research and personalized approaches offer hope for improved outcomes and better quality of life for affected individuals.
To know more about soft tissue sarcoma treatment, visit @ Soft Tissue Sarcoma Treatment Drugs
Key Soft Tissue Sarcoma Therapies and Companies
- Camsirubicin: Monopar Therapeutics
- Lurbinectedin: Jazz Pharmaceuticals
- Liposomal Annamycin (L-Annamycin): Moleculin Biotech, Inc.
- AL3818: Advenchen Laboratories, LLC
- YH001: Tracon Pharmaceuticals Inc.
- CFT8634: C4 Therapeutics, Inc.
- Olaratumab + Doxorubicin: Eli Lilly and Company
- Tazemetostat + Doxorubicin HCl: Epizyme, Inc./Ipsen
- Niraparib: GlaxoSmithKline
- Seclidemstat: Salarius Pharmaceuticals, LLC
- Tinostamustine (EDO-S101): Mundipharma Research Limited
- HFB301001: HiFiBiO Therapeutics
- Tigilanol Tiglate: QBiotics Group Limited
- Pembrolizumab: Merck Sharp & Dohme LLC
- Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy: Polaris Group
- L19TNF and DOXORUBICIN: Philogen S.p.A.
- doxorubicin with AGEN1884 and AGEN2034: Agenus Inc
- APX005M: Apexigen America, Inc.
- MGCD516: Mirati Therapeutics Inc.
Learn more about the FDA-approved drugs for soft tissue sarcoma @ Drugs for Soft Tissue Sarcoma Treatment
Soft Tissue Sarcoma Market Dynamics
The soft tissue sarcoma market dynamics are characterized by a complex interplay of various factors that impact the prevalence, diagnosis, treatment, and research of this rare form of cancer. One of the key drivers of the soft tissue sarcoma market is the increasing incidence of soft tissue sarcoma globally, leading to a growing patient pool seeking medical intervention. Improved awareness among healthcare professionals and patients has also contributed to early detection and diagnosis, resulting in a higher demand for treatment options.
Advancements in medical technology and diagnostic tools have played a vital role in enhancing the accuracy of diagnosis and staging, enabling personalized treatment approaches. Targeted therapies and immunotherapies have emerged as promising treatment modalities, fostering substantial research and development efforts from pharmaceutical companies.
The soft tissue sarcoma market is further influenced by regulatory changes and reimbursement policies, which can impact the accessibility of novel therapies and affect the overall treatment landscape. Additionally, collaborations between academic institutions, research organizations, and pharmaceutical companies have facilitated the exploration of innovative therapies and clinical trials, driving progress in the field.
Despite these positive trends, challenges persist, including high treatment costs, limited availability of effective therapies for specific subtypes, and the rarity of the disease, making clinical trials and data collection more challenging. However, the soft tissue sarcoma market remains dynamic, with ongoing efforts to address these issues, paving the way for improved patient outcomes and a better quality of life for those affected by this challenging disease.
| Soft Tissue Sarcoma Report Metrics | Details |
| Study Period | 2019–2032 |
| Soft Tissue Sarcoma Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Key Soft Tissue Sarcoma Companies | Monopar Therapeutics, Jazz Pharmaceuticals, Moleculin Biotech, Inc., Advenchen Laboratories, LLC, Tracon Pharmaceuticals Inc., C4 Therapeutics, Inc., Eli Lilly and Company, Epizyme, Inc., Ipsen, GlaxoSmithKline, Salarius Pharmaceuticals, LLC, Mundipharma Research Limited, HiFiBiO Therapeutics, QBiotics Group Limited, Merck Sharp & Dohme LLC, Polaris Group, Philogen S.p.A., Agenus Inc, Apexigen America, Inc., Mirati Therapeutics Inc., and others |
| Key Soft Tissue Sarcoma Therapies | Camsirubicin, Lurbinectedin, Liposomal Annamycin (L-Annamycin), AL3818, YH001, CFT8634, Olaratumab + Doxorubicin, Tazemetostat + Doxorubicin HCl, Niraparib, Seclidemstat, Tinostamustine (EDO-S101), HFB301001, Tigilanol Tiglate, Pembrolizumab, Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy, L19TNF and DOXORUBICIN, doxorubicin with AGEN1884 and AGEN2034, APX005M, MGCD516, and others |
Scope of the Soft Tissue Sarcoma Market Report
- Therapeutic Assessment: Soft Tissue Sarcoma current marketed and emerging therapies
- Soft Tissue Sarcoma Market Dynamics: Attribute Analysis of Emerging Soft Tissue Sarcoma Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Soft Tissue Sarcoma Market Access and Reimbursement
Discover more about soft tissue sarcoma drugs in development @ Soft Tissue Sarcoma Clinical Trials
Table of Contents
| 1. | Soft Tissue Sarcoma Market Key Insights |
| 2. | Soft Tissue Sarcoma Market Report Introduction |
| 3. | Soft Tissue Sarcoma Market Overview at a Glance |
| 4. | Soft Tissue Sarcoma Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Soft Tissue Sarcoma Treatment and Management |
| 7. | Soft Tissue Sarcoma Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Soft Tissue Sarcoma Marketed Drugs |
| 10. | Soft Tissue Sarcoma Emerging Drugs |
| 11. | Seven Major Soft Tissue Sarcoma Market Analysis |
| 12. | Soft Tissue Sarcoma Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Unmet Needs |
| 16. | SWOT Analysis |
| 17. | Appendix |
| 18. | DelveInsight Capabilities |
| 19. | Disclaimer |
| 20. | About DelveInsight |
Related Reports
Soft Tissue Sarcoma Epidemiology Forecast
Soft Tissue Sarcoma Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted soft tissue sarcoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Soft Tissue Sarcoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key soft tissue sarcoma companies, including Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, among others.
Clear Cell Sarcoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key clear cell sarcoma companies, including Tesaro, NantPharma, Rafael Pharmaceuticals, Pfizer, among others.
Clear Cell Sarcoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products and the key clear cell sarcoma companies, including Tesaro, NantPharma, Rafael Pharmaceuticals, Pfizer, among others.
Ewing Sarcoma Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Ewing sarcoma companies, including Salarius Pharmaceuticals, Jazz Pharmaceuticals and Pharmamar, Eli Lilly, Pfizer, Bioatla, Cellectar Biosciences, Sumitomo Pharma Oncology, Inhibrx, among others.
Ewing Sarcoma Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key Ewing sarcoma companies, including Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, among others.
Other Trending Reports
Ophthalmic Imaging Equipment Market | Pertussis Market | Recurrent Blood Clots Market | Respiratory Syncytial Virus Market | Systemic Juvenile Idiopathic Arthritis Market | Urethral Stricture Treatment Devices Market | Uterine Serous Carcinoma Market | Zollinger-Ellison Syndrome Market | Acanthamoeba Keratitis Market | Acquired Hemophilia A Pipeline | Acute Pain Market | Age-Related Hearing Loss Medical Device Market | Angio Suites Market | Balloon Catheters Market | Bartonellosis Market | Candidemia Market | Chronic Hand Eczema Market | Chronic Refractory Gout Market | Encephalomyelitis Market | Eosinophilic Gastroenteritis Market | Follicular Lymphoma Market | Head And Neck Squamous Cell Carcinoma Market | Heart Sounds Sensors Market | Heavy Metal Poisoning Market | Hyperinsulinemic Hypoglycemia Market | Hypoplastic Left Heart Syndrome Hlhs Market | Infectious Arthritis/Septic Arthritis Market | Microvascular Angina Market | Mucinoses Market | Necrotizing Enterocolitis Market | Neurofibromatosis 2 Market | Osteochondrodysplasia Market | Plasmacytoma Market | Post-Cardiac Arrest Syndrome Pcas Market | Progressive Familial Intrahepatic Cholestasis Market | Progressive Supranuclear Palsy Market | Pyruvate Kinase Deficiency Market | Recurrent Pericarditis Market | Relapsing Refractory Multiple Myeloma Market | Renal Fanconi Syndrome Market | Wiskott-Aldrich Syndrome Market | Advanced Cancer Pain Management Market | Agoraphobia Market | Alagille Syndrome Market | Atypical Hemolytic Uremic Syndrome Ahus Market | Clinically Isolated Syndrome CIS Market | Conductive Hearing Loss Market | Condyloma Market | Familial Lipoprotein Lipase Deficiency Market | Fucosidosis Market | Glaucoma Drainage Devices Market | H3N2 Infection Market | Hepatitis D Market | Hypopituitarism Market | Hypothalamic Obesity Market | Major Depressive Disorder Market | Muscle Spasticity Market | Musculoskeletal Pain Market Insights | Neurofibromatosis Type 2 Market | Neuronal Ceroid-Lipofuscinoses Market | Paranasal Sinus Cancer Market | Portal Hypertension Market | Propionic Acidemia Market | Systemic Inflammatory Response Syndrome Market Insights | Walking Impairment In Multiple Sclerosis Market | Wet-Age-Related Macular Degeneration Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
